Aptevo Reports 93% Clinical Benefit Rate with Mipleta... Triple Combo in TP53-Mutant AML
APVO Aptevo Therapeutics Inc
$2.60 +11.11%
View chart & analysis → - 1Aptevo Therapeutics (APVO) reported a 93% clinical benefit rate with a mipleta...-based triple regimen in evaluable patients with first-line TP53-mutant AML.
- 2Of 14 evaluable patients receiving mipleta..., venetoclax, and azacitidine, 13 (93%) showed clinical benefit, and 11 (79%) achieved CR or CRi, including 9 complete responses.
- 3The 79% CR/CRi rate compares favorably with the published combined remission rate of 41% for venetoclax plus azacitidine, with remission results nearly doubling that figure.
This 3-line summary is compiled from the report below.
ACCESSWIRE +1 View original ↗
Today's 5 AI picks, all freeNothing hidden: past picks and how they did against the S&P 500.